心力衰竭中的矿物甲基皮质类受体对手:最新情况
João Pedro Ferreira1,2,3, Bertram Pitt4, Faiez Zannad3
1Department of Physiology and Cardiothoracic Surgery, Cardiovascular R&D Centre - UnIC@RISE, Faculty of Medicine of the University of Porto, Portugal (J.P.F.).
Circulation. Heart failure
|November 25, 2024
概括
矿物质皮质类受体抗剂 (MRAs) 有效治疗心力衰竭 (HF). 解决高血症问题可以增加HF患者的MRA使用,改善各种HF类型的结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 矿物质皮质类受体抗剂 (MRA) 在心力衰竭 (HF) 治疗方面有着悠久的历史.
- 类固醇MRA如斯皮罗诺拉克和埃普莱伦已在降低射出分数的高强脉中表现出有效性.
- 最近的进展包括非类固醇MRAs,如菲内伦用于HF,具有保存的射出分数.
研究的目的:
- 批判性地评估MRA在不同HF群体中的使用情况.
- 为了突出体和非体MRA的不断扩大的作用.
- 为了解决和澄清与MRA治疗相关的高胆血症相关的担忧.
主要方法:
- 对临床试验数据和关于HFMRA的既定文献的审查.
- 对不同HF表型 (减少和保留射出分数) 的MRA疗效进行了批判性分析.
- 对安全概况的评估,特别侧重于高血症的管理.
主要成果:
- 螺旋和eplerenone显示在HF中具有降低射出分数的好处.
- MRAs在HF中表现出混合的结果,其中保留了喷射分数,而像finerenone这样的新药显示出有前途.
- 超血症虽然令人担忧,但通过适当的监测和教育,可以控制.
结论:
- 对于广泛的HF患者来说,MRA是有价值的治疗剂.
- 更好地了解和管理高血可以促进更广泛的MRA采用.
- 目前正在进行的研究继续探索MRA在各种高频环境中的潜力.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
01:22Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
01:22Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
01:26Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
590
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
590
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
407
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
407